{
    "Clinical Trial ID": "NCT00003782",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm 1: Doxorubicin + Cyclophosphamide, Then Docetaxel",
        "  Doxorubicin + Cyclophosphamide, then Docetaxel",
        "INTERVENTION 2: ",
        "  Arm 2: Doxorubicin + Docetaxel",
        "  Doxorubicin + Docetaxel"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed invasive adenocarcinoma of the breast",
        "  Confined to the breast and ipsilateral axilla on clinical exam",
        "  Stage I, II, or IIIA (cT1-3, N0-1, M0)",
        "  At least one axillary lymph node with evidence of tumor on histologic exam",
        "  Sentinel node biopsy allowed if followed by axillary dissection",
        "  No suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes, unless proven on biopsy to not be involved with tumor",
        "  No bilateral malignancy or mass in the opposite breast, unless mass is histologically proven to be benign",
        "  Must have undergone either a prior total mastectomy and axillary dissection (modified radical mastectomy) OR",
        "  Prior lumpectomy and axillary dissection",
        "  Patients must receive radiotherapy after randomization (not before) AND after chemotherapy",
        "  Margins must be clear",
        "  No ipsilateral lymph nodes that are fixed to one another or to other structures (N2 disease) and/or any positive nonaxillary lymph nodes (intramammary nodes are considered axillary nodes)",
        "  No histologically evident invasive tumor or ductal carcinoma in situ",
        "  No diffuse tumors by mammography that would not be surgically amenable to lumpectomy",
        "  No other dominant mass in the ipsilateral breast remnant unless one of the following is true:",
        "  Histologically benign",
        "  Surgically removed with clear margins if malignant",
        "  No ulceration, erythema, infiltration of the skin or underlying chest wall (complete fixation), peau d'orange, or skin edema of any magnitude",
        "  Tethering or dimpling of the skin or nipple inversion allowed",
        "  No metastatic disease",
        "  Skeletal pain allowed if bone scan negative for metastases",
        "  Hormone receptor status:",
        "  Estrogen and progesterone status determined",
        "  PATIENT CHARACTERISTICS:",
        "  Age:",
        "  greater than or equal to 18 years",
        "  Sex:",
        "  Female",
        "  Menopausal status:",
        "  Not specified",
        "Performance status:",
        "  Not specified",
        "  Life expectancy:",
        "  At least 10 years, excluding diagnosis of cancer",
        "  Hematopoietic:",
        "  Absolute neutrophil count at least 1,500/mm^3 (may be less, if in the opinion of the investigator, this represents an ethnic or racial variation)",
        "  Platelet count at least 100,000/mm^3* NOTE: *If platelet count is above the upper limit of normal (ULN), significant underlying hematologic disorders must be excluded",
        "  Hepatic:",
        "  Bilirubin no greater than ULN",
        "  Alkaline phosphatase less than 2.5 times ULN*",
        "  SGOT less than 1.5 times ULN*",
        "  No nonmalignant systemic hepatic disease that would preclude study participation NOTE: *Alkaline phosphatase and SGOT cannot both be greater than ULN",
        "  Renal:",
        "  Creatinine no greater than normal",
        "  No nonmalignant systemic renal disease that would preclude study participation",
        "  Cardiovascular:",
        "  No nonmalignant systemic cardiovascular disease that would preclude study participation",
        "  LVEF at least lower limit of normal (LLN) by MUGA or echocardiogram",
        "  No active cardiac disease that would preclude use of doxorubicin or docetaxel, including the following:",
        "  Any prior myocardial infarction",
        "  Angina pectoris requiring anti-anginal medication",
        "  History of congestive heart failure",
        "  Cardiac arrhythmia requiring medication",
        "  Severe conduction abnormality",
        "  Valvular disease with documented cardiac function compromise",
        "  Cardiomegaly on chest x-ray or ventricular hypertrophy on EKG, unless LVEF at least LLN",
        "  Poorly controlled hypertension (diastolic greater than 100 mm/Hg)",
        "  Hypertension well controlled by medication allowed",
        "  Other:",
        "  No grade 2 or greater peripheral neuropathy",
        "  No other prior malignancy within the past 5 years except:",
        "  Effectively treated squamous cell or basal cell skin cancer",
        "  Surgically treated carcinoma in situ of the cervix",
        "  Segmentally resected lobular carcinoma in situ of the ipsilateral or contralateral breast",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective barrier contraception",
        "  No nonmalignant systemic disease that would preclude study participation",
        "  No diabetes with morning fasting blood glucose of 200 mg/dL or greater",
        "  No psychiatric or addictive disorders that would preclude informed consent",
        "  No contraindication to corticosteroids that would preclude study participation",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy:",
        "  No prior immunotherapy for breast cancer",
        "  Chemotherapy:",
        "  No prior chemotherapy for breast cancer",
        "  No prior anthracyclines or taxanes",
        "  No other concurrent investigational chemotherapy",
        "  Endocrine therapy:",
        "  No prior hormonal therapy for breast cancer",
        "  No concurrent hormonal birth control methods or other hormonal therapy",
        "  No concurrent raloxifene, including for osteoporosis",
        "  Concurrent low-dose topical estrogen in the form of conjugated estrogen ring or conjugated estrogen vaginal cream (dose no more than 0.3 mg or 1/8 of an applicator applied vaginally 3 times a week) allowed",
        "  Radiotherapy:",
        "  See Disease Characteristics",
        "  No prior radiotherapy for this malignancy",
        "  Surgery:",
        "  See Disease Characteristics",
        "  No more than 84 days since prior surgery for breast cancer (e.g., lumpectomy, mastectomy, sentinel node biopsy, axillary dissection, or re-excision of lumpectomy margins)",
        "  Other:",
        "  No prior systemic therapy for this malignancy",
        "  No concurrent medications that alter cardiac conduction (e.g., digitalis, beta blockers, or calcium-channel blockers) for cardiac arrhythmia, angina, or congestive heart failure (allowed if administered for other reasons [e.g., hypertension])",
        "  Concurrent bisphosphonates allowed"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Overall Survival",
        "  [Not Specified]",
        "  Time frame: 8 years",
        "Results 1: ",
        "  Arm/Group Title: Arm 1: Doxorubicin + Cyclophosphamide, Then Docetaxel",
        "  Arm/Group Description: Doxorubicin + Cyclophosphamide, then Docetaxel",
        "  Overall Number of Participants Analyzed: 1753",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of patients alive  83",
        "Results 2: ",
        "  Arm/Group Title: Arm 2: Doxorubicin + Docetaxel",
        "  Arm/Group Description: Doxorubicin + Docetaxel",
        "  Overall Number of Participants Analyzed: 1753",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of patients alive  79"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 66/1748 (3.78%)",
        "  Febrile neutropenia 2/1748 (0.11%)",
        "  Cardiac disorders - Other, specify 3/1748 (0.17%)",
        "  Conduction disorder 0/1748 (0.00%)",
        "  Myocardial infarction 0/1748 (0.00%)",
        "  Ventricular arrhythmia 1/1748 (0.06%)",
        "  Left ventricular systolic dysfunction 0/1748 (0.00%)",
        "  Colitis 1/1748 (0.06%)",
        "  Diarrhea 0/1748 (0.00%)",
        "  Duodenal ulcer 0/1748 (0.00%)",
        "Adverse Events 2:",
        "  Total: 43/1748 (2.46%)",
        "  Febrile neutropenia 1/1748 (0.06%)",
        "  Cardiac disorders - Other, specify 1/1748 (0.06%)",
        "  Conduction disorder 0/1748 (0.00%)",
        "  Myocardial infarction 1/1748 (0.06%)",
        "  Ventricular arrhythmia 0/1748 (0.00%)",
        "  Left ventricular systolic dysfunction 1/1748 (0.06%)",
        "  Colitis 1/1748 (0.06%)",
        "  Diarrhea 1/1748 (0.06%)",
        "  Duodenal ulcer 1/1748 (0.06%)"
    ]
}